HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on BioLine Rx (NASDAQ:BLRX) and maintained a price target of $21, as stated by analyst Joseph Pantginis.
June 03, 2024 | 4:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on BioLine Rx and maintained a price target of $21, indicating continued confidence in the company's potential.
The reiteration of a Buy rating and maintenance of a $21 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100